Literature DB >> 25531350

Mechanisms and models for intestinal fibrosis in IBD.

Carlo De Salvo1, Shuvra Ray, Theresa T Pizarro.   

Abstract

Intestinal fibrosis is a common outcome in IBD leading to significant morbidity that, to date, has no effective medical treatment. Current knowledge regarding potential mechanism(s) of intestinal fibrogenesis and stricture formation is limited, due in large part to the lack of relevant animal models. Although conventional models possess aspects that are advantageous to study specific mechanisms involved in gut fibrosis, most lack the features of a spontaneously occurring process leading to the formation of intestinal fibrotic lesions following mucosal inflammatory events and the ability to investigate the natural course of disease over time. This review aims to discuss established and novel animal models of gut fibrosis, particularly focusing on the advantages and disadvantages of each model system and the insights they bring to our understanding of the mechanisms of fibrogenesis. In fact, recent enhancements to existing models and the expansion of novel animal models of gut fibrosis is opening up multiple avenues for investigation which should stimulate progress in our mechanistic understanding of intestinal fibrogenesis and facilitate the development of effective pharmacotherapy in an area of significant unmet need.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25531350     DOI: 10.1159/000367822

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  7 in total

Review 1.  Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis.

Authors:  Shuvra Ray; Carlo De Salvo; Theresa T Pizarro
Journal:  Curr Opin Gastroenterol       Date:  2014-11       Impact factor: 3.287

Review 2.  Animal models for studying epithelial barriers in neonatal necrotizing enterocolitis, inflammatory bowel disease and colorectal cancer.

Authors:  Tiaosi Xing; Rolando Camacho Salazar; Yan-Hua Chen
Journal:  Tissue Barriers       Date:  2017-08-10

Review 3.  Berberine and its derivatives represent as the promising therapeutic agents for inflammatory disorders.

Authors:  Qiukai Lu; Yifan Fu; Heng Li
Journal:  Pharmacol Rep       Date:  2022-01-27       Impact factor: 3.024

Review 4.  Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease.

Authors:  Giorgos Bamias; Theresa T Pizarro; Fabio Cominelli
Journal:  Inflamm Bowel Dis       Date:  2022-03-02       Impact factor: 7.290

5.  Can Rodent Model of Acetic Acid-Induced Colitis be Used to Study the Pathogenesis of Colitis-Associated Intestinal Fibrosis?

Authors:  Saravanan Subramanian; Chao Du; Xiao-Di Tan
Journal:  J Invest Surg       Date:  2020-09-21       Impact factor: 1.972

6.  Expression of decorin in intestinal tissues of mice with inflammatory bowel disease and its correlation with autophagy.

Authors:  Huazhou Zhao; Hongqing Xi; Bo Wei; Aizhen Cai; Ting Wang; Yi Wang; Xudong Zhao; Yanjing Song; Lin Chen
Journal:  Exp Ther Med       Date:  2016-11-15       Impact factor: 2.447

7.  Intervention of oncostatin M-driven mucosal inflammation by berberine exerts therapeutic property in chronic ulcerative colitis.

Authors:  Heng Li; Chunlan Feng; Chen Fan; Yang Yang; Xiaoqian Yang; Huimin Lu; Qiukai Lu; Fenghua Zhu; Caigui Xiang; Zongwang Zhang; Peilan He; Jianping Zuo; Wei Tang
Journal:  Cell Death Dis       Date:  2020-04-24       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.